Description: Aelis Farma S.A., a clinical-stage biopharmaceutical company, focuses on the discovery and development of drug candidates for the treatment of unaddressed central nervous system disorders. It is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate in Phase 2b clinical trials for use in the treatment of the negative consequences of excessive cannabis use; and AEF0217, a drug candidate in Phase 1 clinical trials for use in the treatment of cognitive impairments due to a hyperactivity of the CB1 receptor, as well as cognitive deficits observed in Down syndrome. The company was incorporated in 2013 and is based in Bordeaux, France.
Home Page: www.aelisfarma.com
146 rue Léo Saignat
Bordeaux,
33000
France
Phone:
33 5 57 57 37 70
Officers
| Name | Title |
|---|---|
| Dr. Pier Vincenzo Piazza M.D., Ph.D. | CEO & Director |
| Ms. Valérie Scappaticci | Chief Financial Officer |
| Stephanie Monlezun | Chief Operating Officer |
Exchange: PA
Country: FR
Currency: Euro (€)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 42.4375 |
| Price-to-Book MRQ: | 5.8505 |
| Price-to-Sales TTM: | 21.4585 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 23 |